<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618912</url>
  </required_header>
  <id_info>
    <org_study_id>15768</org_study_id>
    <nct_id>NCT05618912</nct_id>
  </id_info>
  <brief_title>Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment</brief_title>
  <official_title>Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be randomized either to receive standard daily dressing or hydrocolloid&#xD;
      dressing using a randomization generator. After closing the wound with the sutures,the scar&#xD;
      will be covered by a hydrocolloid dressing, which will be left in place for 7&#xD;
      days(Experimental) or the standard dressing (Control) that will be covered with petrolatum&#xD;
      jelly and bandaging during this time period, which has to be re-applied daily. Patients and&#xD;
      dermatologic surgeons will then complete surveys 7 days, 30 days, and 90 days after surgery&#xD;
      to evaluate the cosmetic appearance of these scars.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2022</start_date>
  <completion_date type="Anticipated">August 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 17, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each patient will have the surgical scar treated with either type of intervention</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cosmetic outcome</measure>
    <time_frame>7 days</time_frame>
    <description>Patient and surgeon assessment of cosmetic outcome using modified visual analogue scar scale. The minimum value is 1 and the maximum value is 10. 1 is the worst possible scar appearance and 10, is the best possible scar appearance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cosmetic outcome</measure>
    <time_frame>30 days</time_frame>
    <description>Patient and surgeon assessment of cosmetic outcome using modified visual analogue scar scale. The minimum value is 1 and the maximum value is 10. 1 is the worst possible scar appearance and 10, is the best possible scar appearance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cosmetic outcome</measure>
    <time_frame>90 days</time_frame>
    <description>Patient and surgeon assessment of cosmetic outcome using modified visual analogue scar scale. The minimum value is 1 and the maximum value is 10. 1 is the worst possible scar appearance and 10, is the best possible scar appearance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>7 days, 30 days, 90 days</time_frame>
    <description>Complication rate including hematoma, seroma, wound infection requiring antibiotics, opening and drainage of wound, dehiscence. Complications will be assessed by physicians other than operating surgeon</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Scar</condition>
  <condition>Skin Scarring</condition>
  <condition>Skin Cancer</condition>
  <condition>Wound Heal</condition>
  <condition>Wound of Skin</condition>
  <condition>Surgical Wound</condition>
  <condition>Patient Satisfaction</condition>
  <condition>Patient Preference</condition>
  <condition>Surgical Incision</condition>
  <arm_group>
    <arm_group_label>hydrocolloid dressing arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After informed consent and closing the wound with the sutures, the scar will be covered by a hydrocolloid dressing, which will be left in place for 7 days (Experimental)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Petrolatum jelly dressing arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>and the other group of patients (control), after closing the wound with the sutures, the scar will be covered with petrolatum jelly during this time period, which has to be re-applied daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrocolloid dressing</intervention_name>
    <description>A single hydrocolloid dressing will be applied to the surgical site for 7 days following dermatologic surgery</description>
    <arm_group_label>hydrocolloid dressing arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Petrolatum jelly dressing</intervention_name>
    <description>The patient with the control wound will be covered with petrolatum jelly during this time period, which has to be re-applied daily.</description>
    <arm_group_label>Petrolatum jelly dressing arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult &gt; 18 years of age&#xD;
&#xD;
          2. Linear scars&#xD;
&#xD;
          3. Patients underwent conventional excision or Mohs micrographic surgery for primary&#xD;
             cutaneous cancer or other cutaneous condition that required surgical intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Scar localization on acral or hair bearing sites&#xD;
&#xD;
          2. Patients unable to converse in English&#xD;
&#xD;
          3. Patients requiring flap or graft for closure of wound&#xD;
&#xD;
          4. History of allergy to adhesives&#xD;
&#xD;
          5. Patient using topical chemotherapy agents on the surgical site or planning to start it&#xD;
             within 3 months after surgery&#xD;
&#xD;
          6. Use of hydrocolloid dressings for post-operative wound care in the past&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IU Health Physicians Dermatology Meridian Crossing</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syril Keena T Que, MD, MPH</last_name>
      <phone>317-944-4000</phone>
      <email>sque@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Syril Keena T Que, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria C Bell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Morr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arslan Iqbal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Holmes SP, Rivera S, Hooper PB, Slaven JE, Que SKT. Hydrocolloid dressing versus conventional wound care after dermatologic surgery. JAAD Int. 2021 Dec 21;6:37-42. doi: 10.1016/j.jdin.2021.11.002. eCollection 2022 Mar.</citation>
    <PMID>34993497</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 23, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Syril Keena Que</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Dermatology</investigator_title>
  </responsible_party>
  <keyword>scar</keyword>
  <keyword>dermatologic surgery</keyword>
  <keyword>wound healing</keyword>
  <keyword>wound of skin</keyword>
  <keyword>skin cancer</keyword>
  <keyword>surgical incision</keyword>
  <keyword>patient satisfaction</keyword>
  <keyword>patient preference</keyword>
  <keyword>cosmetic outcome</keyword>
  <keyword>scar appearance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Cicatrix</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

